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Introduction
Basal lamina is specialized net of proteins and proteo-
glycans of extracellular matrix (ECM). The basal lam-
ina acts as a selective barrier to the movement of the
cell between epithelia of  blood vessels and neighbor-
ing tissue, as a filter for molecules, and acts as an
anchor for normal cells. The basal lamina may induce
differentiation and restrains migration of the normal
cells [1-3]. Ability of the cancerous cells to degrada-
tion of proteins and proteoglycan components of basal
lamina, extracellular matrics and stroma of adenocar-
cinoma is connected with possibility of metastasis. To
metastasize, cancer cell must penetrate a blood or a
lymphatic vessel by crossing the basal lamina and
endothelial lining of the vessel so as to enter the blood
or lymph vessel, exit from the vessel elsewhere in the
body, and then grow in the new site, forming the
micromethastasis. Micrometastases must produce cells
that survive and proliferate in new environment [2,3].
In development of neoplasm and its metastasis impor-
tant role play structures of saccharide chains of glyco-
conjugates and enzymes that take a part in their syn-
thesis and degradation i.e. glycosyltransferases and
glycosidases [4,5]. Exoglycosidases facilitate degrada-
tion of proteins, by degradation of the oligosaccharide
chains of glycoproteins covering protein cores. Lyso-
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Abstract: Lysosomal exoglycosidases: N-acetyl-β-D-hexosaminidase (HEX), β-D-galactosidase (GAL), α-L-fucosidase
(FUC) and α-D-mannosidase (MAN) modify oligosaccharide chains of glycoconjugates in endoplasmatic reticulum and/or
Golgi apparatus and degrade them in lysosomes. In acid environment of lysosome, exoglycosidases degrade oligosaccha-
ride chains of glycoproteins, glycolipids and glycosaminoglycans by eliminating single sugars from the edges of oligosac-
charide chains. Neoplasms change biochemical processes in tissues and may significantly change the activity of many
enzymes including the activity of lysosomal exoglycosidasses in serum and urine of persons with neoplasmatic diseases.
The aim of the present paper was evaluation the activity of HEX, GAL, FUC and MAN in serum and urine of patients with
pancreatic adenocarcinoma. Serum and urine samples were collected from 15 patients with adenocarcinoma of the pancreas
and 15 healthy persons. The activity of lysosomal exoglycosidases was determined by the method of Marciniak et al. adapt-
ed to serum and urine of patients with adenocarcinoma of the pancreas. Our results indicate significant decrease in activity
of GAL (p=0.037) in serum of patients with pancreatic adenocarcinoma, significant increase in activity of HEX (p<0.001)
and FUC (p=0.027) in serum, and HEX (p=0.003) in urine, as well as significant decrease of FUC (p=0.016) and MAN
(p=0.029) in urine o patients with adenocarcinoma of the pancreas, in comparison to the control group. Increase in activity
of some lysosomal enzymes in serum and urine of pancreatic adenocarcinoma patients, may indicate on destruction of pan-
creatic tissue by pancreatic adenocarcinoma. Determination of the HEX, GAL, FUC and MAN in serum and urine may be
useful in diagnostics of pancreatic adenocarcinoma.
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somal exoglycosidases: N-acetyl-β-D-hexosaminidase
(HEX – E.C. 3.2.1.30), β-D-galactosidase (GAL – E.C.
3.2.1.23), α-L-fucosidase (FUC – E.C. 3.2.1.51) and α-
D-mannosidase (MAN – E.C. 3.2.1.24) in acid environ-
ment of lysosome release single sugars from the edges
of oligosaccharide chains of glycoconjugates [6].
The aim of our research was determination the
activity of lysosomal exoglycosidases: HEX, GAL,
FUC and MAN in serum and urine as a potential
markers of pancreatic adenocarcinoma.
Materials and methods
Patients. The urine and blood samples were obtained from 15
patients (7 males and 8 females) aged from 44 to 74 years (mean
59±9.29 years), who were diagnosed histopathologically as bear-
ing pancreatic adenocarcinoma (G 2). All patients were operated in
1st Department of General Surgery and Endocrinology of the Med-
ical University of Bia³ystok. Before the examination, patients were
subjected neither to chemotherapy, nor radiotherapy. The control
group included 15 healthy people (6 females and 9 males) aged
from 22 to 62 years (mean 35±10.45 years). 
The clinical exclusion criteria from the study were: diabetes,
rheumatoid arthritis, glomerular nephritis, alcohol abuse.
Sample material. The blood samples were obtained from the
elbow vein before operation and then they were clotted. The urine
samples were taken from the middle stream of the morning portion.
The urine and blood were centrifuged at 4,000 × g for 10 min. The
supernatant fluids were portioned and stored at the temperature of
-80°C. 
Glycosidases activity assays. HEX, GAL, FUC and MAN activi-
ty were determined by Marciniak's et al. method [7] modified by
Szajda et al., [8,9] for determination of exoglycosidases in serum
and urine. To 10 μL of appropriately diluted urine and serum were
added: 40 μL of 0.1M phosphate-citrate buffer at pH 4.7 for HEX
and pH 4.3 for remaining exoglycosidases, and 30 μL of 20 mM
substrate solution of p-Nitrophenyl-N-acetyl-ß-D-glucosaminide,
for determination of HEX; p-Nitrophenyl-β-D-galactopyranoside
for GAL, p-Nitrophenyl-α-L-fucopyranoside for FUC and p-Nitro-
phenyl-α-D-mannopyranoside for MAN determination (Sigma, St.
Louis, MO, USA), in 0.1 M of phosphate-citrate buffer at pH 4.7
for HEX and 4.3 for the remaining exoglycosidases. The mixtures
were incubated for 60 min at a temperature of 37°C. The reactions
were stopped by adding 200 μL of 0.2M borate buffer at pH 9.8.
The activity of lysosomal exoglycosidases corresponding to the
amounts of released p-nitrophenol, were measured in 405 nm,
using the microplates reader ELX800TM and computer program KC
junior (Bio-Tek Instruments, Winooski, VT, USA). The concentra-
tion of the activity of lysosomal exoglycosidases in serum and
urine was expressed in pKat/mL.
Quality control the determinations of HEX, GAL, FUC and
MAN. Reproducibility tests (precision in the series; within-run and
day-to-day) of the HEX, GAL, FUC and MAN determinations
were performed in serum and urine of 6 control persons according
to the standard procedures (Table 1, 2) [10]. 
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Table 1. HEX, GAL, FUC and MAN (within-run) activity in blood serum and urine of 6 healthy people
Ethical issues. The study was approved by the Bioethical Committee
of Bialystok Medical University who gave permission numbers R-I-
003/153/2005 and R-I-003/300/2006 for our examinations.
Statistical analysis. The data are presented as means±standard
deviation (SD). Statistical analysis was performed using the SPSS®
statistical package (SPSS Inc., Chicago, IL, USA). The data were
verified for normal distribution using the Kolmogorov-Smirnov
test, and their distributions were found to be normal, the Student's-
t test for unpaired observations was used to determine the signifi-
cance of differences, with p<0.05 was considered statistically sig-
nificant. The sensitivity and specificity of the method were calcu-
lated used NCSS statistical package.
Results
Coeficients of variations (CV) calculated on the basis
of determinations performed in the series (within-run)
of serum and urine of 6 control persons were in the
case of HEX: 5.125±1.004 for serum and 6.837±1.484
for urine [11]. Coefficients of variations calculated on
the basis of determinations performed in the series
(within-run) of serum and urine of 6 control persons
were in the case of: GAL 8.262±1.110 for serum and
6.234±1.455 for urine, in the case of FUC:
8.792±0.668 for serum and 6.780±1.710 for urine and
for MAN: 9.312±1.421 for serum and 7.193±1.860 for
urine (Table 1). 
Coefficients of variations for determinations
between series (day-to-day, between-day) based on
measurements performed in serum and urine obtained
from 6 healthy persons were in the case of HEX:
11.622±0.864 for serum and 14.927±2.256 for urine,
GAL: 13.069±1.831 for serum and 15.719±0.620 for
urine, FUC: 11.606±1.469 for serum and
11.877±2.553 for urine, and MAN: 15.870±2.160 for
serum and 15.785±1.165 for urine (Table 2).
We found significant decrease in activity of GAL
(p=0.037), significant increase in activity of HEX
(p<0.001) and FUC (p=0.027) in serum of patients
with pancreatic cancer and significant increase in
activity of HEX (p=0.003) in urine, as well as signifi-
cant decrease in urinary activity of FUC (p=0.016) and
MAN (p=0.029) of patients with pancreatic adenocar-
cinoma. We did not observed significant differences in
activities of MAN in serum and GAL in urine of pan-
creas adenocarcinoma patients in comparison to the
control (Table 3, Fig. 1, 2). 
In examining the power of the test we found huge
effect of HEX in the serum (effect size=2.41) and very
large effect for urine (effect size=1.28), large effect of
GAL (effect size=0.80) and FUC (effect size=0.85) in
serum and FUC (effect size=0.96) and MAN (effect
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Table 2. HEX, GAL, FUC and MAN (day-to-day, between-day) activity in blood serum and urine of 6 healthy people
size=0.86) in the urine, a medium effect for GAL
(effect size=0.52) in the urine and small effect for
MAN (effect size=0.31) in serum. 
These results proved a high diagnostic value (AUC:
0.97778 and 0.71556; p[AUC=0.5]: 0.0001 and
0.0251) for the activity of HEX and FUC in serum,
respectively as well as (AUC: 0.9000; p[AUC=0.5]:
0.0001) for HEX respectively in the urine of patients
with pancreatic adenocarcinoma, in comparison with
the activity in healthy people (Table 4). 
The concentration of HEX activity in serum of
patients with pancreatic cancer has 93.33% sensitivity
and 100% specificity at the value of cut-off > 494.42
pKat/mL, GAL has 40.00% sensitivity and 33.33%
specificity for the value of cut-off >70.76 pKat/mL,
FUC has 73.33% sensitivity and 60.00% specificity
for the value of cut-off >113.62 pKat/mL, and MAN
has 53.33% sensitivity and 66.67% specificity for the
value of cut-off >106.83 pKat/mL (Table 5, Fig. 3a).
The concentration of HEX activity in urine of patients
with pancreatic cancer has 86.67% sensitivity and
85.71% specificity for the value of cut-off >168.63
pKat/mL, GAL has 60.00% sensitivity and 57.14%
specificity for the value of cut-off >71.11 pKat/mL,
FUC has 33.33% sensitivity and 28.57% specificity
for the value of cut-off >45.40 pKat/mL, and MAN has
53.33% sensitivity and 21.43% specificity for the
value of cut-off >39.68 pKat/mL (Table 5, Fig. 3b).
Discussion 
Currently, for diagnostics and monitoring of pancreat-
ic adenocarcinoma are used USG and computer
tomography as well as protein markers associated
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Fig. 1. Concentrations of the activities of HEX, GAL, FUC and
MAN in blood serum of patients with adenocarcinoma of the pan-
creas. c: control group; Ca: pancreatic adenocarcinoma. 
Fig. 2. Concentrations of the activities of HEX, GAL, FUC and
MAN in urine of patients with adenocarcinoma of the pancreas. c:
control group; Ca: pancreatic adenocarcinoma. 
Fig. 3. Sensitivity and specificity of determination of HEX, GAL, FUC and MAN activity in (a) blood serum and (b) urine of patients
with adenocarcinoma of the pancreas.
with pancreatic adenocarcinoma: carcinoembrionic
antigen (CEA) and carcinous antigen of alimentary
tract (CA 19.19) [12,13]. 
Serum concentration of CEA significantly increas-
es in colon adenocarcinoma as well as adenocarcino-
mas of: pancreas, stomach, lungs, reproductive organs
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Table 3. Activities of HEX, GAL, FUC and MAN in serum and urine of patients with pancreatic adenocarcinoma
Table 4. Diagnostic value the concentration of HEX, GAL, FUC and MAN activity in blood serum and urine of patients with adenocar-
cinoma of the pancreas
n – number of cases included in the analysis; n(-) – number of negative cases; n(+) – number of positive cases; AUC – area under curve; SE – standard
error for assessment of AUC; 95%C.I. (AUC) – 95% confidence interval of determined AUC; interval that with 95% confidence contains the real value of
AUC for the population; p(AUC=0.5) – p-value of the test checks a diagnostic value of the method. If AUC varies significantly from 0.5, it means that the
method differentiates significantly the study cases into positive and negative.
Table 5. Sensitivity and specificity of determination of HEX, GAL, FUC and MAN activity in blood serum and urine of patients with
adenocarcinoma of the pancreas
and urinary bladder. Significant increase in serum con-
centrations of CEA occurs in nonepithelial neoplasms
(neuroblastomas, sarcomas, lymphomas) and in non
neoplastic diseases as: hepatitis and hepatic cirrhosis,
chronic pancreatitis, chronic gastric and duodenal
ulcer disease, ulcerative colitis as well as in some
physiological states e.g. pregnancy. CEA has limited
diagnostic sensitivity and specificity, which made dif-
ficult use of CEA in diagnostics of defined neoplasm
and use in screening tests [14]. 
Ca 19-9 antigen now used in diagnosis of pancreat-
ic adenocarcinoma, initially was determined in diag-
nostics of colon cancer [15]. Presently it is generally
understood that concentration of Ca 19-9 increases in
cases of carcinomas of alimentary tract, particularly
pancreas and gallbladder and in inflammatory diseases
of alimentary tract, liver and pancreas. [14,15].
Healthy cells and tissues demonstrate stable enzy-
matic activity. In pathological states activity of one or
several enzymes change. Neoplastic cells produce and
secrete to extracellular space normal and pathological
components of connective tissue, and among them gly-
cosaminoglycans, proteoglycans and collagens. Neo-
plastic cells produce different hydrolytical enzymes,
and among them lysosomal exoglycosidases which are
able to degradation of connective tissue barriers [3,16]. 
In our previous investigations we analyzed mostly
usefulness of N-acetyl-β-hexosaminidase (HEX) and
its isoenzymes A and B, the most active of lysosomal
exoglycosidases, in detection and monitoring of neo-
plasmatic diseases. Determination the activity of HEX,
HEX A and B in serum may be useful in differential
diagnosis cancers of thyroid, renal and pancreatic ade-
nocarcinoma, because in serum of thyroid increases
only HEX A activity [17]; HEX, HEX A i HEX B sig-
nificantly increase in real cancer [18,19], instaed in
panreatic adenocarcinoma significantly increase HEX
and HEX A [20]. We found high diagnostic value of
determination the activity of HEX, HEX A and HEX B
in serum and urine of patients with colon cancer [11].
Determination the activity of HEX A and HEX B in
cancerous renal tissue by colormetric and electropho-
cusing methods, gave similar results [19]. As colori-
metric method is simpler, easier and cheaper, therefore
we recommend it for determinations multiple samples.
Colon cancer is one of the main death causes,
because of late cancer diagnosis. In our opinion deter-
mination the activities of N-acetyl-β-D-hex-
osaminidase (HEX), β-galactosidase (GAL), α-man-
nosidase (MAN) and α-fucosidase (FUC) in serum
and urine alongside of routinelly determined cancer
markers may create substantial progress in diagnostic
of pancreatic cancer. Our results (Table 3, Figs 1, 2),
indicate on significant differences in activity of lyso-
somal exoglycosidases in serum and urine of patients
with pancreatic adenocarcinoma in comparison to
patients with colon cancer [9]. Our preliminary results
indicate on possibility of differential diagnosis pancre-
atic and colon cancers, by determination of lysosomal
exoglycosidases. In serum of patients with pancreatic
adenocarcinoma, activity of GAL significantly decreas-
es whereas there is lack of differences in GAL activity
in urine (Table 3, Fig. 1). On the other hand in serum
and urine of patients with colon cancer activity of GAL
significantly increases in comparison to control [9].
There was significant decrease in activity of FUC and
MAN in urine of patients with pancreatic adenocarcino-
ma (Table 3, Fig. 2) and no changes in colon carcinoma,
in comparison to control, which may help in differential
diagnosis of pancreatic and colon carcinomas [9]. We
observed significant increase in activity of FUC
(p<0.0001) in serum of patients with colon cancer [9],
but in serum of patients with pancreatic cancer, signifi-
cance was at the level of p=0.0269 (Table 3, Fig. 1). 
In a summary it may be stated, that our results sug-
gest possibility of easy and cheap determinations the
activity of lysosomal exoglycosidases in serum and
urine for diagnostics of pancreatic cancer. Our investi-
gations suggest possibility of use of profile of lysoso-
mal exoglycosidases in differential diagnosis of pan-
creatic adenocrcinoma with other neoplasms.
Conclusions
1. Pancreatic adenocarcinoma significantly changes
activity of lysosomal exoglycosidases in serum and
urine.
2. Determination the activity of lysosomal exogly-
cosidases in serum and urine may be suitable for
differential diagnosis of pancreatic cancer. 
3. Simplicity and low costs of exoglycosidases deter-
minations in serum and urine imply their use in
screening of cancers.
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